
Pfizer poised to buy Metsera in $10 bn deal after bidding war
The Peninsula
San Francisco, United States: Pfizer was poised to seal a takeover of Metsera on Saturday after its improved offer won over the biotechnology startup...
San Francisco, United States: Pfizer was poised to seal a takeover of Metsera on Saturday after its improved offer won over the biotechnology startup's board and Danish challenger Novo Nordisk called a halt to a back-and-forth bidding war.
Metsera, a US firm specializing in obesity treatments, has been the subject of escalating offers from US pharma giant Pfizer and Novo Nordisk, which makes the weight-loss drug Wegovy and the antidiabetic medication Ozempic.
In a press release Friday, Metsera said Pfizer had made an improved offer to acquire it for up to $86.25 per share, in a deal worth around $10 billion.
Metsera said its board "unanimously recommends that... stockholders approve the adoption of the amended Pfizer merger agreement and approve the merger."
It added that it expected to close the deal "promptly" after a shareholder meeting on November 13.










